Vitezslav Kolek

TL;DR: The concept that immunogenetic background may at least partly account for the clinical heterogeneity of sarcoidosis is supported, as data obtained in independent studies in two European populations (Italian and Czech) seem to support that.

TL;DR: Five new clinical phenotypes of sarcoidosis have been identified by analysing organ manifestations of 1932 patients and will be useful to recruit homogenous cohorts in future biomedical studies.

TL;DR: The results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome and the administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi -1 when compared to their BMI-1 positive counterparts.

TL;DR: Efficacy signals were seen with alisertib/paclitaxel in relapsed/refractory SCLC and c-Myc expression and mutations in cell cycle regulators may be potential predictive biomarkers of alisERTib efficacy; further prospective validations are warranted.

TL;DR: The 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient’s IPF cohort is observed and DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenodone, and should be routinely evaluated during follow-up examinations.